← Back to Screener
Rocket Pharmaceuticals, Inc. Warrant (RCKTW)
Price$0.01
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-86.17%
Price vs S&P 500 (4W)-22.99%
VGM Score5.29
All Metrics
Price vs S&P 500 (YTD)-74.37%
10-Day Avg Trading Volume0.02M
3-Month Avg Trading Volume0.02M
52-Week High$0.08
26-Week Price Return-78.25%
13-Week Price Return-58.60%
3-Month Return Std Dev198.19%
Year-to-Date Return-68.31%
5-Day Price Return-21.43%
Month-to-Date Return-20.62%
Price vs S&P 500 (13W)-66.86%
Beta2.76x
52-Week Low$0.01
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RCKTWRocket Pharmaceuticals, Inc. Warrant | — | — | F | $0.01 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Rocket Pharmaceuticals is a late-stage biopharmaceutical company developing gene therapies for rare pediatric diseases. Its pipeline includes five clinical and preclinical programs targeting Fanconi Anemia, Leukocyte Adhesion Deficiency, Pyruvate Kinase Deficiency, Danaon Disease, and Infantile Malignant Osteopetrosis. The company focuses on research, development, and commercialization of its gene therapy candidates.